Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Lonitoclax (ZE50-0134) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Select Low-grade Lymphomas

NCT06708897 is registered in ClinicalTrials.gov with Lomond Therapeutics Holdings, Inc. as lead sponsor.

NCT NCT06708897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06708897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Lonitoclax (ZE50-0134) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Select Low-grade Lymphomas
Lead sponsor
Lomond Therapeutics Holdings, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 8, 2025
Completion date
July 31, 2028
Enrollment
84 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cll (chronic lymphocytic leukemia), cll / sll, lymphoplasmacytic lymphoma/waldenström macroglobulinemia, marginal zone lymphoma(mzl), sll (small lymphocytic lymphoma)